Shummary:
SPT Labtech and Semarion have partnered to integrate their respective technologies—automated liquid handling and microcarrier platforms—to streamline and scale adherent cell assay development for drug discovery.

Takeaways:

  • The collaboration combines SPT Labtech’s firefly automation system with Semarion’s SemaCyte microcarriers to simplify and miniaturize complex cell-based assays.
  • This integration enhances flexibility, reproducibility, and scalability for workflows like high-content imaging and cell painting.
  • The partnership will generate application protocols and proof-of-concept data to support broader adoption in drug screening and discovery.

SPT Labtech, a global provider in innovative laboratory automation, today announced a strategic collaboration with Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs. The partnership will integrate SPT Labtech’s firefly liquid handling platform with Semarion’s SemaCyte microcarrier technology to develop a flexible, scalable, and automated workflow that simplifies and accelerates key stages of adherent cell assay development.

“This collaboration is an exciting opportunity to explore how cutting-edge technologies like Semarion’s microcarriers can be seamlessly integrated into flexible automation platforms like firefly. We’re looking forward to developing tools that truly empower scientists working at the forefront of cellular research,” says Maryia Karpiyevich, product development scientist at SPT Labtech.

By integrating SPT Labtech’s versatile firefly liquid handling platform with Semarion’s microcarrier-based approach, the collaboration will overcome long-standing challenges in miniaturizing and automating complex cell biology processes. 

SPT Labtech and Semarion Are Setting New Standards

Together, SPT Labtech and Semarion will set a new standard for flexibility and scalability in cell-based assay design—enabling researchers to more easily adapt workflows to their unique applications while improving efficiency and reproducibility, for example, high-content image based assays such as cell painting.

“This partnership demonstrates the impact of combining our innovative microcarrier technology with agile automation. By Integrating our SemaCyte platform with SPT Labtech’s firefly system, we’re unlocking a new class of flexible, miniaturized workflows that streamline assay development and unlock more scalable discovery pipelines,” says Jeroen Verheyen, CEO and Co-Founder at Semarion.

Collaboration Opening More Doors to Innovation

The collaboration will explore the development of joint application protocols, proof-of-concept data, and workflow optimization strategies, with the goal of providing researchers with more adaptable tools for cell-based discovery.

“We are committed to supporting emerging technologies that align with our mission to make life in the lab easier. This partnership reflects our dedication to innovation that meets researchers where they are—scaling up, scaling down, and adapting as science evolves,” says Morten Frost, chief commercial officer at SPT Labtech.

Featured Image: Lightfieldstudiosprod | Dreamstime.com